Bio


My academic training and research experience have equipped me with multidisciplinary skills and knowledge of molecular biology and immunology.

I led two projects when I was an undergraduate, in which I got primary academic learning. My team member and I investigated the bacteria content in drinking water from two types of machines that are commonly used in colleges under the guidance of our experimental microbiology teacher Zhihong Zhong. Secondly, we produced a hybridoma cell line secreting monoclonal antibody against the core antigen of the hepatitis C virus (HCV) to develop an ELISA kit for the detection of HCV under the guidance of Dr. Rushi Liu and Minjing Liao.

Thereafter, as a Ph. D. candidate at Xiaoming Feng’s lab, my research primarily focused on understanding the biology of regulatory T cells (Treg) and CD11c+ myeloid cells using cutting-edge single-cell sequencing and conditional knockout mice under healthy and disease conditions. We first revealed the heterogeneity and bifurcated differentiation pathway of human Tregs from normal donors and transplanted patients at the single-cell transcriptome level. A subsequent first and corresponding author publication identified a key innate responsive protein in CD11c+ alveolar macrophages, NRP2, that protects mice from lung injury via promoting the phagocytosis of neutrophils. I also participated in two projects regarding the role of a serine/threonine kinase, LKB1, in mice CD11c+ dendritic cells from lymphoid tissues and adipose tissue with diet-induced obesity. These academic experiences guided me into a strong passion and independent capacities for biomedical studies.

For my postdoctoral training, I will focus on developing Treg therapies and genetic stem cell therapy to cure patients with IPEX syndrome (a severe autoimmune disease) at preclinical and clinical stages, and other immune disorders. My sponsor Dr. Rosa Bacchetta is a well-known leader in treating IPEX patients and developing Treg therapies. My co-mentor Dr. Maria Grazia Roncarolo is a well-recognized pediatric immunologist and also one of the pioneers in the stem cell and gene therapy field, who discovered the type 1 regulatory T cells or Tr1 cells and translate the scientific discoveries into novel Treg therapies. Both of them have an excellent record of training postdoctoral fellows. The proposed projects will provide me with great opportunities in cutting-edge technology and translational research and outline a set of career development including grant writing, public presentation, and lab management, which will enhance my ability to become an independent investigator and help me to reach my goal of developing efficient and safe Treg therapies for a wide range of immune disorders and associated human diseases.

Honors & Awards


  • Outstanding Graduate Award, Peaking Union Medical College (7/2022)
  • Scholarship (4 times), Peaking Union Medical College (9/2017-7/2022)
  • Outstanding Graduate Thesis Award, Hunan Normal University (5/2017)
  • Scholarship (3 times), Hunan Normal University (9/2012-7/2017)

Stanford Advisors


All Publications


  • Alveolar macrophage-derived NRP2 curtails lung injury while boosting host defense in bacterial pneumonia JOURNAL OF LEUKOCYTE BIOLOGY Wang, B., Guo, W., Qiu, C., Sun, Y., Zhao, C., Wu, C., Lai, X., Feng, X. 2022; 112 (3): 499-512

    Abstract

    Clearance of airway intruders by immune cells is required to resolve infectious pneumonia. However, the molecular mechanisms underlying this process remain elusive. Here, we demonstrated that alveolar macrophage (AM)-derived neuropilin 2 (NRP2) plays an essential role in controlling severe pneumonia by enhancing microbial clearance. Mice with conditional deletion of the NRP2 gene in AM had persistent bacteria, uncontrolled neutrophil influx, and decreased survival during Escherichia coli-induced pneumonia. In vitro assays demonstrated that NRP2 could bind to CD11b+ Ly6Glo/+ neutrophils and promote their capacities in phagocytosis and killing of bacteria, which is partially contributed to the increased expression of TLR4 and TNF-a. These findings collectively revealed that AM-derived NRP2 protects the lungs from unwanted injury by promoting the clearance of invading pathogens. This study might provide a promising diagnostic biomarker and therapeutic target for severe pneumonia.

    View details for DOI 10.1002/JLB.4A1221-770R

    View details for Web of Science ID 000783166200001

    View details for PubMedID 35435271

  • Single-cell transcriptomic analysis reveals disparate effector differentiation pathways in human T-reg compartment NATURE COMMUNICATIONS Luo, Y., Xu, C., Wang, B., Niu, Q., Su, X., Bai, Y., Zhu, S., Zhao, C., Sun, Y., Wang, J., Liu, M., Sun, X., Song, G., Cui, H., Chen, X., Huang, H., Wang, H., Han, M., Jiang, E., Shi, L., Feng, X. 2021; 12 (1): 3913

    Abstract

    Human FOXP3+ regulatory T (Treg) cells are central to immune tolerance. However, their heterogeneity and differentiation remain incompletely understood. Here we use single-cell RNA and T cell receptor sequencing to resolve Treg cells from healthy individuals and patients with or without acute graft-versus-host disease (aGVHD) who undergo stem cell transplantation. These analyses, combined with functional assays, separate Treg cells into naïve, activated, and effector stages, and resolve the HLA-DRhi, LIMS1hi, highly suppressive FOXP3hi, and highly proliferative MKI67hi effector subsets. Trajectory analysis assembles Treg subsets into two differentiation paths (I/II) with distinctive phenotypic and functional programs, ending with the FOXP3hi and MKI67hi subsets, respectively. Transcription factors FOXP3 and SUB1 contribute to some Path I and Path II phenotypes, respectively. These FOXP3hi and MKI67hi subsets and two differentiation pathways are conserved in transplanted patients, despite having functional and migratory impairments under aGVHD. These findings expand the understanding of Treg cell heterogeneity and differentiation and provide a single-cell atlas for the dissection of Treg complexity in health and disease.

    View details for DOI 10.1038/s41467-021-24213-6

    View details for Web of Science ID 000668769000012

    View details for PubMedID 34162888

    View details for PubMedCentralID PMC8222404

  • Control of T-reg cell homeostasis and immune equilibrium by Lkb1 in dendritic cells NATURE COMMUNICATIONS Chen, S., Fang, L., Guo, W., Zhou, Y., Yu, G., Li, W., Dong, K., Liu, J., Luo, Y., Wang, B., Li, Z., Zhao, C., Sun, Z., Shen, Y., Leng, Q., Zhou, D., Han, Z., Huang, H., Ren, H., Xu, G., Feng, X. 2018; 9: 5298

    Abstract

    To balance immunity and tolerance, the endogenous pool of Foxp3+ regulatory T (Treg) cells is tightly controlled, but the underlying mechanisms of this control remain poorly understood. Here we show that the number of Treg cells is negatively regulated by the kinase Lkb1 in dendritic cells (DCs). Conditional knockout of the Lkb1 gene in DCs leads to excessive Treg cell expansion in multiple organs and dampens antigen-specific T cell immunity. Lkb1-deficient DCs are capable of enhancing, compared with wild-type DCs, Treg cell proliferation via cell-cell contact involving the IKK/IKBα-independent activation of the NF-κB/OX40L pathway. Intriguingly, treating wild-type mice with lipopolysaccharide selectively depletes Lkb1 protein in DCs, resulting in Treg cell expansion and suppressed inflammatory injury upon subsequent challenge. Loss of Lkb1 does not obviously upregulate proinflammatory molecules expression on DCs. We thus identify Lkb1 as a regulatory switch in DCs for controlling Treg cell homeostasis, immune response and tolerance.

    View details for DOI 10.1038/s41467-018-07545-8

    View details for Web of Science ID 000453057400004

    View details for PubMedID 30546010

    View details for PubMedCentralID PMC6294005

  • Spatial Transcriptomics Analysis Reveals that CCL17 and CCL22 are Robust Indicators of a Suppressive Immune Environment in Angioimmunoblastic T Cell Lymphoma (AITL) Front. Biosci. (Landmark Ed) Du, J., Qiu, C., Li, W., Wang, B., Han, X., Lin, S., Fu, ., Hou, J., Huang, Z. 2022; 27 (9): 270

    View details for DOI 10.31083/j.fbl2709270